Successful Treatment of Chronic Decubitus Ulcer with 0.1% Dirhamnolipid Ointment

Piljac, Ante; Stipčević, Tamara; Piljac-Žegarac, Jasenka; Piljac, Goran

doi:10.2310/7750.2008.07052

Cited by 38 publications

(23 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The dirhamnolipid ␣-L-rhamnopyranosyl-(1-2)␣-L-rhamnopyranosyl-3-hydroxydecanoyl-3-hydroxydecanoic acid ("BAC-3") produced by Pseudomonas aeruginosa is well tolerated and promoted faster healing in studies examining burn wounds in mice and rats; these studies led to its successful application in a single clinical case of chronic decubitus ulcer (17,18). However, differences in wound types, wound sizes, animal models, surfactant types, and biosurfactant mixtures make comparisons between these studies difficult.…”

Section: Discussionmentioning

confidence: 99%

“…In contrast, biosurfactants are a diverse group of surfactants produced by certain species of yeast or bacteria, which represent a more sustainable and perceived environmentally friendly alternative to traditional surfactants. There is increasing evidence that microbial biosurfactants, as well as possessing industrially valuable properties of detergency, emulsification, and foaming, also have significant bioactivities, including inhibitory or antibacterial adjuvant activities against various microorganisms (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18) and specific anticancer activity (19).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Adjuvant Antibiotic Activity of Acidic Sophorolipids with Potential for Facilitating Wound Healing

Lydon

Baccile

Callaghan

et al. 2017

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The sophorolipid class of biosurfactants is finding increasing use in personal care as well as pharmaceutical products and has the potential to disrupt biofilm formation and inhibit the growth of a variety of clinically relevant organisms. In order to investigate potential biomedical applications of sophorolipids derived from nonpathogenic organisms, we fractionated and purified glycolipid biosurfactant sophorolipids produced by the yeast Starmerella bombicola, which yielded nonacetylated acidic C 18:1 congeners that were essentially free from other contaminants (Ͼ95% purity). These acidic sophorolipids have antimicrobial activities against the nosocomial infective agents Enterococcus faecalis and Pseudomonas aeruginosa, with significant reductions in CFU at concentrations of as low as 5 mg ml Ϫ1 . In addition, the sophorolipid showed similar effects against the same two bacterial strains when combined with kanamycin or cefotaxime. As a potential use of these sophorolipids is as a component of topically applied creams for the treatment of wound infections, it is clear that they must have no demonstrable adverse effect on wound healing. To assess this, we evaluated mammalian cell toxicity in vitro using viability tests, which revealed no adverse effect on either endothelial or keratinocyte-derived cell lines with sophorolipid concentrations of Ͻ 0.5 mg ml Ϫ1 . In addition, in vivo experiments using a mouse skin wounding assay revealed that the time course of healing wounds was unaffected by the application of sophorolipid-containing creams, and histological examination of regenerated skin tissue confirmed that the healing process was similar to that observed for control animals, with no evidence of inflammation. These results are consistent with the suggestion that acidic sophorolipids can be used as a component of antimicrobial creams to reduce the risk of wound infection during healing.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Adjuvant Antibiotic Activity of Acidic Sophorolipids with Potential for Facilitating Wound Healing

Lydon

Baccile

Callaghan

et al. 2017

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…6a) and previously case on burn wounded rats9. RHA has even been applied to cure the decubitus ulcer of patient33, further indicating its safety in human external application. Moreover, RHA also showed high safety in oral administration (ED 50 > 5000 mg/kg)34 and subcutaneous injection (low toxicity at 120 mg/kg per day)9 in rodents.…”

Section: Discussionmentioning

confidence: 75%

Targeted killing of myofibroblasts by biosurfactant di-rhamnolipid suggests a therapy against scar formation

Shen

Jiang

Shao

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Pathological myofibroblasts are often involved in skin scarring via generating contractile force and over-expressing collagen fibers, but no compound has been found to inhibit the myofibroblasts without showing severe toxicity to surrounding physiological cells. Here we report that di-rhamnolipid, a biosurfactant secreted by Pseudomonas aeruginosa, showed potent effects on scar therapy via a unique mechanism of targeted killing the myofibroblasts. In cell culture, the fibroblasts-derived myofibroblasts were more sensitive to di-rhamnolipid toxicity than fibroblasts at a concentration-dependent manner, and could be completely inhibited of their specific functions including α-SMA expression and collagen secretion/contraction. The anti-fibrotic function of di-rhamnolipid was further verified in rabbit ear hypertrophic scar models by presenting the significant reduction of scar elevation index, type I collagen fibers and α-SMA expression. In this regard, di-rhamnolipid treatment could be suggested as a therapy against skin scarring.

show abstract

“…Originally rhamnolipids attracted attention as agents for oil recovery and bioremediation [14] but there is increasing interest in the potential biomedical application of these molecules [15] due to their wide range of biological activities including formation of ion channels in lipid bilayer membranes, regulation of intracellular signaling pathways, induction of cell differentiation and cell-signaling [15]. Although rhamnolipids, and glycolipid-biosurfactants in general, have not been tested on any nervous tissue cell type nor delivered to brain, previous studies with the di-rhamnolipid BAC-3 indicate that this glycolipid has cell-type specific effects on skin [16], exhibits anti-inflammatory and immune-modulating properties [17a] [17b] and enhances healing and tissue regeneration in an animal model of full-thickness burn wounds [18a] [18b] and on chronic decubitus wound in human [19]. Given common developmental origins of skin and brain and high expression of GSLs in both, we hypothesized that BAC-3 might also be effective on nervous tissue cells and tested its activity on NSCs.…”

Section: Introductionmentioning

confidence: 99%

Stimulation of adult neural stem cells with a novel glycolipid biosurfactant

2013

View full text Add to dashboard Cite

Glycolipids are amphipatic molecules which are highly expressed on cell membranes in skin and brain where they mediate several key cellular processes. Neural stem cells are defined as undifferentiated, proliferative, multipotential cells with extensive self-renewal and are responsive to brain injury. Di-rhamnolipid: α-L-rhamnopyranosyl-(1-2)α-L-rhamnopyranosyl-3-hydroxydecanoyl-3-hydroxydecanoic acid, also referred to as di-rhamnolipid BAC-3, is a glycolipid isolated from bacteria Pseudomonas aeruginosa. In the previous studies di-rhamnolipid enhanced dermal tissue healing and regeneration. The present study provides the first assessment of di-rhamnolipid, and glycolipid-biosurfactants in general, on the nervous system. Treatment of neural stem cells isolated from the lateral ventricle of adult mice and cultured in defined media containing growth factors at 0.5 and 1 μg/ml of di-rhamnolipid increased the number of neurospheres (2.7 and 2.8 fold, respectively) compared to controls and this effect remained even after passaging in the absence of di-rhamnolipid. Additionally, neural stem cells treated with di-rhamnolipid at 50 and 100 μg/ml in defined media supplemented with fetal calf serum and without growth factors exhibited increased cell viability indicating an interaction between di-rhamnolipid and serum components in the regulation of neural stem cells and neuroprogenitors. Intracerebroventricular administration of di-rhamnolipid at 300 and 120 ng/day increased the number of neurospheres (1.3 and 1.63 fold, respectively) that could be derived from the anterior lateral ventricles of adult mice. These results indicate that di-rhamnolipid stimulates proliferation of neural stem cells and increases their endogenous pools which may have therapeutic potential in managing neurodegenerative or neuropsychiatric disorders and promoting nervous tissue regeneration following injury.

show abstract

Successful Treatment of Chronic Decubitus Ulcer with 0.1% Dirhamnolipid Ointment

Abstract: This case demonstrates that application of dirhamnolipid resulted in the healing of a chronic decubitus ulcer in an elderly, debilitated patient and might be a useful therapy to improve healing of decubitus ulcers.

Cited by 38 publications

References 17 publications

Adjuvant Antibiotic Activity of Acidic Sophorolipids with Potential for Facilitating Wound Healing

Adjuvant Antibiotic Activity of Acidic Sophorolipids with Potential for Facilitating Wound Healing

Targeted killing of myofibroblasts by biosurfactant di-rhamnolipid suggests a therapy against scar formation

Stimulation of adult neural stem cells with a novel glycolipid biosurfactant

Contact Info

Product

Resources

About